Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038187 (
starvation
)
24,951
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A heat shock-resistant mutant of the budding yeast Saccharomyces cerevisiae was isolated at the mutation frequency of 10(-7) from a culture treated with ethyl methane sulfonate. Cells of the mutant are approximately 1,000-fold more resistant to lethal heat shock than those of the parental strain. Tetrad analysis indicates that phenotypes revealed by this mutant segregated together in the ratio 2+:2- from heterozygotes constructed with the wild-type strain of the opposite mating type, and are, therefore, attributed to a single nuclear mutation. The mutated gene in the mutant was herein designated hsr1 (heat shock response). The hsr1 allele is recessive to the HSR1+ allele of the wild-type strain. Exponentially growing cells of hsr1 mutant were found to constitutively synthesize six proteins that are not synthesized or are synthesized at reduced rates in HSR1+ cells unless appropriately induced. These proteins include one hsp/G0-protein (hsp48A), one hsp (hsp48B), and two G0-proteins (
p73
, p56). Heterozygous diploid (hsr1/HSR1+) cells do not synthesize the proteins constitutively induced in hsr1 cells, which suggests that the product of the HSR1 gene might negatively regulate the synthesis of these proteins. The hsr1 mutation also led to altered growth of the mutant cells. The mutation elongated the duration of G1 period in the cell cycle and affected both growth arrest by sulfur
starvation
and growth recovery from it. We discuss the problem of which protein(s) among those constitutively expressed in growing cells of the hsr1 mutant is responsible for heat shock resistance and alterations in the growth control.
...
PMID:A heat shock-resistant mutant of Saccharomyces cerevisiae shows constitutive synthesis of two heat shock proteins and altered growth. 638 38
The
p73
gene located at 1p36.3 encodes for a protein with significant similarity to p53. To investigate the penetrance of
p73
in gastric carcinogenesis, we analyzed the expression, allelotype, and mutation of
p73
in five cell lines and 75 tissues. Although extremely low levels of
p73
expression were observed in all noncancerous gastric tissues and four of five cell lines, a significant elevation of
p73
was detected in 37 of 39 (94.9%) carcinoma tissues. Furthermore, a tumor-specific increase of
p73
was identified in 14 of 16 (87.5%) matched sets. Allelotyping analysis using a StyI or BanI polymorphism revealed that 5 of 21 (23.8%) informative carcinomas, but none of 19 noncancerous cases, express
p73
biallelically, suggesting the transcriptional activation of a silent allele in a subset of cancers. Whereas the transcription of an active allele was markedly induced by serum
starvation
or clump formation of the cells, treatment with 5-aza-2'deoxycytidine activated a silent allele with a subsequent up-regulation of an active allele, supporting the genomic imprinting and autoregulation of the gene. Allelic deletion or mutation of the gene was not found, and no association of
p73
expression with the mutational status of p53 or expression of p21Waf1 was recognized. Taken together, this study argues that
p73
is not a target of genetic alteration in gastric carcinogenesis and suggests that overexpression of
p73
might be triggered by physiological stresses accompanied with outgrowth of tumors, such as hypoxia or nutrient deprivation.
...
PMID:Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. 1081 95
p73
transcription factors are members of the p53 family and participate in developmental processes and DNA damage response.
p73
expression was shown to be regulated during the cell cycle, suggesting that
p73
might play a role in cell growth and might be a target for cyclin-dependent kinases. Consistent with this hypothesis, we discovered that
p73
interacts physically with various cyclins (A, B, D, and E). Furthermore, cyclin A/CDK1/2, cyclin B/CDK1/2, and cyclin E/CDK2 complexes can phosphorylate multiple
p73
isoforms in vitro at threonine 86. A specific antibody directed against phosphorylated Thr86 showed that this site is phosphorylated in vivo and that such phosphorylation is regulated in a cell cycle-dependent manner. Thr86 phosphorylation is induced during S phase and is maximal in the G2/M phase. Accordingly inhibitors of cell growth, such as p16 and serum
starvation
, reduce Thr86 phosphorylation. Finally, we found that cyclin-dependent kinase (CDK)-dependent Thr86 phosphorylation represses the ability of
p73
to induce endogenous p21 expression. Our results demonstrate that
p73
proteins are targets of CDK complexes and that phosphorylation on Thr86 by CDKs regulates
p73
functions.
...
PMID:Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. 1267 26
Evading programmed cell death is a common event in tumour development. The p53 family member,
p73
, is a potent inducer of death and a determinant of chemotherapeutic response, but different to p53, is rarely mutated in cancer. Understanding cell death pathways downstream of p53 and
p73
is therefore pivotal to understand both the development and treatment of malignant disease. Recently, p53 has been shown to modulate autophagy--a membrane trafficking process, which degrades long-lived proteins and organelles. This requires a p53 target gene, DRAM, and both DRAM and autophagy are critical for p53-mediated death. We report here that TA-
p73
also regulates DRAM and autophagy, with different TA-
p73
isoforms regulating DRAM and autophagy to varying extents. RNAi knockdown of DRAM, however, revealed that
p73
's modulation of autophagy is DRAM-independent. Also,
p73
's ability to induce death, again different to p53, is neither dependent on DRAM nor autophagy. In contrast to TA-
p73
, deltaN-
p73
is a negative regulator of p53-induced and
p73
-induced autophagy, but does not affect autophagy induced by amino-acid
starvation
. These studies, therefore, represent not only the first report that
p73
modulates autophagy but also highlight important differences in the mechanism by which
starvation
, p53 and
p73
regulate autophagy and how this contributes to programmed cell death.
...
PMID:p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. 1730 43
p53-upregulated modulator of apoptosis (PUMA) plays an essential role in p53-dependent apoptosis following DNA damage. PUMA also mediates apoptosis independent of p53. In this study, we investigated the role and mechanism of PUMA induction in response to serum
starvation
in p53-deficient cancer cells. Following serum
starvation
, the binding of Sp1 to the PUMA promoter significantly increased, whereas inhibition of Sp1 completely abrogated PUMA induction.
p73
was found to be upregulated by serum
starvation
and mediate PUMA induction through the p53-binding sites in the PUMA promoter. Sp1 and p73beta appeared to cooperatively activate PUMA transcription, which is inhibited by the phosphoinsitide 3-kinase (PI3K)-protein kinase B (AKT) pathway. Furthermore, knockdown of PUMA suppressed serum
starvation
-induced apoptosis in leukemia cells. Our results suggest that transcription factors Sp1 and
p73
mediate p53-independent induction of PUMA following serum
starvation
to trigger apoptosis in human cancer cells.
...
PMID:Sp1 and p73 activate PUMA following serum starvation. 1857 60
Cardiovascular disease is a leading cause of death worldwide, particularly in Western societies. During an ischaemic insult, ventricular pressure from the heart is diminished as a result of cardiac myocyte death by necrosis and apoptosis. Autophagy is a process whereby cells catabolise intracellular proteins in order to generate ATP in times of stress such as nutrient
starvation
and hypoxia. Emerging evidence suggests that autophagy plays a positive role in cardiac myocyte survival during periods of cellular stress performing an important damage limitation function. By promoting cell survival, cardiac myocyte loss is reduced thereby minimising the potential of heart failure. In contrast, it has been reported that autophagy can also be a form of cell death. By considering the various animal models of autophagy, we examine the role of the Signal Transducers and Activator of Transcription (STAT) proteins in the autophagic response. Additionally we review the role of the tumour suppressor, p53 and its family member
p73
and their potential role in the autophagic response.
...
PMID:Autophagy in the stress-induced myocardium. 2220 25
As a member of the p53 gene family,
p73
regulates cell cycle arrest, apoptosis, neurogenesis, immunity and inflammation. Recently,
p73
has been shown to transcriptionally regulate selective metabolic enzymes, such as cytochrome c oxidase subunit IV isoform 1, glucose 6-phosphate dehydrogenase and glutaminase-2, resulting in significant effects on metabolism, including hepatocellular lipid metabolism, glutathione homeostasis and the pentose phosphate pathway. In order to further investigate the metabolic effect of
p73
, here, we compared the global metabolic profile of livers from
p73
knockout and wild-type mice under both control and
starvation
conditions. Our results show that the depletion of all
p73
isoforms cause altered lysine metabolism and glycolysis, distinct patterns for glutathione synthesis and Krebs cycle, as well as an elevated pentose phosphate pathway and abnormal lipid accumulation. These results indicate that
p73
regulates basal and
starvation
-induced fuel metabolism in the liver, a finding that is likely to be highly relevant for metabolism-associated disorders, such as diabetes and cancer.
...
PMID:p73 regulates basal and starvation-induced liver metabolism in vivo. 2637 72
Medulloblastoma is the most common solid primary brain tumor in children. Remarkable advancements in the understanding of the genetic and epigenetic basis of these tumors have informed their recent molecular classification. However, the genotype/phenotype correlation of the subgroups remains largely uncharacterized. In particular, the metabolic phenotype is of great interest because of its druggability, which could lead to the development of novel and more tailored therapies for a subset of medulloblastoma.
p73
plays a critical role in a range of cellular metabolic processes. We show overexpression of
p73
in a proportion of non-WNT medulloblastoma. In these tumors,
p73
sustains cell growth and proliferation via regulation of glutamine metabolism. We validated our results in a xenograft model in which we observed an increase in survival time in mice on a glutamine restriction diet. Notably, glutamine
starvation
has a synergistic effect with cisplatin, a component of the current medulloblastoma chemotherapy. These findings raise the possibility that glutamine depletion can be used as an adjuvant treatment for
p73
-expressing medulloblastoma.
...
PMID:TAp73 is a marker of glutamine addiction in medulloblastoma. 2898 57
More than 50% of colon cancers bear mutations in p53, one of the most important tumor suppressors, and its family members p63 or
p73
are expected to contribute to inhibiting the progression of colon cancers. The AP2 family also acts as a tumor suppressor. Here we found that
p73
and AP2 are able to activate NEU4, a neuraminidase gene, which removes the terminal sialic acid residues from cancer-associated glycans. Under serum
starvation
, NEU4 was up-regulated and one of the NEU4 target glycans, sialyl Lewis X, was decreased, whereas
p73
and AP2 were up-regulated. Sialyl Lewis X levels were not, however, decreased under
starvation
conditions in
p73
- or AP2-knockdown cells. p53 and AP2 underwent protein-protein interactions, exerting synergistic effects to activate p21, and interaction of p53 with AP2 was lost in cells expressing the L350P mutation of p53. The homologous residues in p63 and
p73
are L423 and L377, respectively. The synergistic effect of p53/p63 with AP2 to activate genes was lost with the L350P/L423P mutation in p53/p63, but
p73
bearing the L377P mutation was able to interact with AP2 and exerted its normal synergistic effects. We propose that
p73
and AP2 synergistically activate the NEU4 promoter in colon cancer cells.
...
PMID:Synergistic activation of the NEU4 promoter by p73 and AP2 in colon cancer cells. 3070 Aug 26